Aprogen Biologics Inc. (003060.KS) Stock

003060.KS logo

Aprogen Biologics Inc.

003060.KSSouth Korea
Healthcare

Company profile

Aprogen Biologics reported revenue of 73.23 billion KRW for fiscal year 2025, up 8.7% from fiscal year 2024. Its largest business segment, Pharmaceutical Business Division, brought in 85% of segment revenue in fiscal year 2024. Our analysis of its filings shows revenue shrinking from 87.36 billion KRW in fiscal year 2023 to 73.23 billion KRW in fiscal year 2025, 8.4% a year on average. Aprogen Biologics reports about 262 full-time employees.

What stands out

  • It reported a net loss in each of its last 3 fiscal years, after a profit of 12.64 billion KRW in fiscal year 2022; the loss widened from 104.98 billion KRW in fiscal year 2024 to 170.33 billion KRW in fiscal year 2025.
  • Its net profit margin over the last four reported quarters was -90.9%, against a median of -3.6% for 5 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Aprogen Biologics Inc.

Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Aprogen Medicines Inc.57.55%
  • Aprogen Biologics Inc.0.48%
  • Jung-Chool Kim0.009119 %0.01%
  • Sung Nao0.005429 %0.01%
  • Sung-Ho Kang0.005153 %0.01%

Share of the company, as of September 25, 2026

Leadership

  • Jeong-Chool Kim — Chief Executive Officer
  • Jung-Chul Kim — President

How much revenue does Aprogen Biologics make?

Aprogen Biologics reported 73.23 billion KRW in revenue for fiscal year 2025, up 8.7% from 67.38 billion KRW in fiscal year 2024.

What is Aprogen Biologics's largest business segment?

Pharmaceutical Business Division, with 57.57 billion KRW or 85% of segment revenue in fiscal year 2024. Next: Bio Business Division (14%) and Other Sales (1%).

What companies are similar to Aprogen Biologics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bcworld Pharm. Co., Ltd. (200780.KQ), Korea Arlico Pharm Co.,Ltd. (260660.KQ), Sanigen (188260.KQ), Seoul Pharma Co., Ltd (018680.KQ).

Has Aprogen Biologics made a profit in recent years?

Net income by fiscal year: FY2021, 8.10 billion KRW; FY2022, 12.64 billion KRW; FY2023, a loss of 118.27 billion KRW; FY2024, a loss of 104.98 billion KRW; FY2025, a loss of 170.33 billion KRW. It reported a net loss in 3 of these 5 years.

How does Aprogen Biologics' profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Aprogen Biologics, -90.9%; Bcworld Pharm. Co., Ltd. (200780.KQ), -3.6%; Korea Arlico Pharm Co.,Ltd. (260660.KQ), -1.5%; Sanigen (188260.KQ), -27.4%; Seoul Pharma Co., Ltd (018680.KQ), 3.4%; Telcon RF Pharmaceutical. Inc. (200230.KQ), -28.3%.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees262
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
6, 31, Ogeum-ro 19-gil, Seoul
Phone
82 2 561 4011
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Aprogen Biologics Inc. (003060.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003060.KS

LinkedInLinkedInXXYouTubeYouTube